Atossa Therapeutics Launches 'COVID-19 HOPE Drug' Development Program That 'uses a novel combination of two drugs that have been previously approved by the FDA for other diseases'
8:01 am ET April 16, 2020 (Benzinga) Print
Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need, today announced a new drug development program called COVID-19 HOPE. The program uses a novel combination of two drugs that have been previously approved by the FDA for other diseases. The goal of the COVID-19 HOPE program is to develop a therapy to improve lung function and reduce the amount of time that COVID-19 patients are on ventilators.
“The rapidly increasing number of COVID-19 patients needing mechanical ventilation is deeply worrisome, as more than one-third of these patients will never recover lung function and will die on the ventilator,” stated Dr. Steven Quay, President and CEO of Atossa Therapeutics. “The problem is confounded by the fact that hospitals may soon be facing a ventilator shortage and a vaccine could take more than a year to develop. The two drugs we intend to combine, which we call AT-H201, have been approved by the FDA for other diseases and are supported by a dozen clinical studies in close to 800 patients. We plan to quickly initiate and complete clinical studies so that we can obtain FDA approval to bring this treatment to market as soon as possible.”
Atossa has filed comprehensive provisional patent applications related to AT-H201 and intends to apply to the
News 
Market Data 
Discover 
